Compositions and methods for obtaining an improved lung function

Abstract

A pharmaceutical composition for obtaining an improved lung function in a human or an animal lung affected by airway obstruction such as COPD or asthma, is provided. The composition comprises a pharmacologically effective amount of activated carbon comprising adsorbed iodine and/or an adsorbed iodide salt and a sodium/iodide symporter inhibitor, such as perchlorate. Additionally, a method for obtaining an improved lung function in a human or animal lung affected by airway obstruction, such as COPD or asthma, is provided. The method comprises the steps of administering a pharmacologically effective amount of activated carbon comprising adsorbed iodine and/or an adsorbed iodide salt, and administering a sodium/iodide symporter inhibitor, such as perchlorate, in connection to the administration of the pharmacologically effective amount of activated carbon comprising adsorbed iodine and/or an adsorbed iodide salt.

1 . A pharmaceutical composition for obtaining an improved lung function in a human or an animal lung affected by chronic obstructive pulmonary disease (COPD) or asthma, comprising:
 a pharmacologically effective amount of activated carbon comprising adsorbed iodine (I 2 ) and/or an adsorbed iodide salt; and   perchlorate.   
     
     
         2 . (canceled) 
     
     
         3 . The pharmaceutical composition according to  claim 1 , wherein the ratio of adsorbed iodine and/or iodide salt and perchlorate is in the range of 200:1 to 1:5. 
     
     
         4 . The pharmaceutical composition according to  claim 1 , wherein the ratio of adsorbed iodine and/or iodide salt and perchlorate is in the range of 100:1 to 1:1. 
     
     
         5 . The pharmaceutical composition according to  claim 1 , wherein the amount of perchlorate is in the range of from 1 mg to 1000 mg. 
     
     
         6 . The pharmaceutical composition according to  claim 1 , wherein the amount of perchlorate is in the range of from 25 mg to 500 mg. 
     
     
         7 . The pharmaceutical composition according to  claim 1 , wherein the amount of perchlorate is in the range from 50 mg to 250 mg. 
     
     
         8 . (canceled) 
     
     
         9 . The pharmaceutical composition according  claim 1 , wherein the amount of activated carbon comprising adsorbed iodine and/or an adsorbed iodide salt and perchlorate is from 0.10 g to 500 g. 
     
     
         10 . The pharmaceutical composition according to  claim 1 , wherein the amount of activated carbon comprising adsorbed iodine and/or an adsorbed iodide salt and perchlorate is from 0.5 g to 100 g. 
     
     
         11 . The pharmaceutical composition according to  claim 1 , wherein the amount of activated carbon comprising adsorbed iodine and/or an adsorbed iodide salt and perchlorate is from 1 g to 25 g. 
     
     
         12 . The pharmaceutical composition according to  claim 1 , wherein the adsorbed iodide salt is an alkali metal iodide or earth alkali metal iodide salt. 
     
     
         13 . The pharmaceutical composition according to  claim 1 , wherein the perchlorate is in the form of a perchlorate salt. 
     
     
         14 . The pharmaceutical composition according to  claim 1 , wherein the pharmaceutical composition is a pharmaceutical composition for oral administration. 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . The pharmaceutical composition according to  claim 1 , for obtaining an improved lung function in a human or an animal lung affected by chronic obstructive pulmonary disease (COPD) or asthma, administered in a dosage regimen of 0.10 g to 500 g daily. 
     
     
         19 . A kit for obtaining an improved lung function in a human or an animal lung affected by chronic obstructive pulmonary disease (COPD) or asthma, comprising:
 a first pharmaceutical composition, comprising a pharmacologically effective amount of activated carbon comprising adsorbed iodine and/or an adsorbed iodide salt; and   a second pharmaceutical composition, comprising perchlorate.   
     
     
         20 . (canceled) 
     
     
         21 . A method for obtaining an improved lung function in a human or an animal lung affected by chronic obstructive pulmonary disease (COPD) or asthma, comprising the steps of: administering to the human or animal a pharmacologically effective amount activated carbon comprising adsorbed iodine and/or an adsorbed iodide salt; and administering perchlorate in connection to the administration of the pharmacologically effective amount of activated carbon comprising adsorbed iodine and/or an adsorbed iodide salt. 
     
     
         22 - 23 . (canceled) 
     
     
         24 . The method according to  claim 21 , comprising administering to the human or animal the pharmaceutical composition according to  claim 1 . 
     
     
         25 . The method according to  claim 21 , wherein the administration of the pharmacologically effective amount of activated carbon comprising adsorbed iodine and/or an adsorbed iodide salt is oral administration to the human or animal. 
     
     
         26 . The method according to  claim 21 , wherein the administration of the perchlorate is oral administration to the human or animal.